WGS | Jotup

Breakthrough whole genome report for embryos created during IVF delivers 100x data for parents, peer reviewed validation published

Retrieved on:

星期一, 四月 15, 2024

Risk, Pregnancy, Birth, WGS, Parent, IVF, Genetics, DNA, DSM-IV codes, Harvard Medical School, Genome, Multimedia, Molina Healthcare, Cancer, SAN, Interest, Vaccine

Orchid published its clinical validation of whole genome embryo screening, a step forward in IVF and genetic screening.

Key Points:

Orchid published its clinical validation of whole genome embryo screening, a step forward in IVF and genetic screening.
Until now, standard genetic screening for embryos read less than 1% of an embryo's genome, which left most conditions undetected until pregnancy, birth, or even through childhood into adulthood.
Then, it could take years to accurately diagnose these conditions, causing harm, stress, and cost to impacted individuals and their families.
Now, Orchid have proven their ability to use whole-genome sequencing (WGS) to successfully read >99% of an embryo's genome, providing 100x more data than traditional tests.

NGS Strategies for Vaccine Development and Surveillance of Respiratory Viruses, Upcoming Webinar Hosted by Xtalks

Retrieved on:

星期一, 四月 15, 2024

Public, Infection, Research and development, WGS, RNA, Doctor of Philosophy, Virus, Viral, NGS, Vaccine

TORONTO, April 15, 2024 /PRNewswire-PRWeb/ -- In the landscape of infectious diseases, next-generation sequencing (NGS) has emerged as a transformative technology, offering unparalleled insights into the complex dynamics of respiratory RNA viruses and critical gene sequences associated with viral infection. This webinar delves into the multifaceted applications of NGS, spanning from viral typing and targeted gene sequencing to whole-genome analysis, with a particular focus on its utility in outbreak tracing and clinical diagnostics.

Key Points:

In this free webinar, discover cutting-edge advancements in next-generation sequencing (NGS) techniques tailored for analyzing respiratory RNA viruses, offering insights into viral diversity and evolution.
The featured speaker will discuss how NGS enhances vaccine development efforts by uncovering crucial information on viral diversity, evolution and potential vaccine targets essential for effective immunization strategies.
Register for this webinar today to gain insights into NGS sequencing techniques tailored for analyzing respiratory RNA viruses with a focus on vaccine development.
Join Kirthi Kumar Kutumbaka, PhD, Scientific Manager, Research & Development, Eurofins Viracor Biopharma Services , for the live webinar on Wednesday, May 1, 2024, at 11am EDT (4pm BST/UK).

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

Retrieved on:

星期四, 四月 4, 2024

WGS, GeneDx

STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024.

Key Points:

STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024.
Management will host a conference call that day to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call are required to register online.
A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .

To Bolster Global Efforts in Combating Antibiotic-Resistant Bacteria KFSH&RC Scientists Discover New Bacteria Species: Riyadhensis

Retrieved on:

星期一, 三月 25, 2024

WGS, Health, Disease, Education, Patient, Research, Hospital, Bacteria, Pseudomonas aeruginosa, RC, KFSH, Infection, Intensive care medicine, Newsweek, ICU, Vaccine

RIYADH, Saudi Arabia, March 25, 2024 (GLOBE NEWSWIRE) -- In a ground-breaking development, scientists at King Faisal Specialist Hospital and Research Centre (KFSH&RC) have identified a new species of bacteria, referred to as "Stenotrophomonas Riyadhensis" through the application of whole-genome sequencing (WGS) technology. This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies. Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.

Key Points:

This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies.
Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.
This represents substantial progress in combating antibiotic resistance, developing pharmaceuticals, and preventing the spread of diseases.
Furthermore, this approach lays the groundwork for scientific collaboration at all levels, enhancing global efforts to combat antibiotic resistance.

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

Retrieved on:

星期五, 三月 15, 2024

Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended December 31, 2023.

Key Points:

With this significant repositioning completed, Nebula Genomics can now deliver low-cost, high-precision genomic diagnostics across North America and the global market.
This agreement presents the possibility for significant expansion of its global footprint and paves the way for prospective future revenue streams.
Research and development costs for the year ended December 31, 2023 and 2022 were $1.4 million and $0.7 million, respectively.
Diluted earnings per share for the years ended December 31, 2023 and 2022 were $(0.98) and $1.02, respectively.

GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics

Retrieved on:

星期四, 三月 14, 2024

Diagnosis, WGS, P130, HZ, P180, Conference, Genetic testing, SLC16A2, CMA, Patient, Medical genetics, Research, A-DNA, Impact, American College, VUS, Fire, ACMG, Syndrome, GeneDx, Analysis, Medical device

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.

Key Points:

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
These findings represent improved data quality from pipeline and platform improvements.
Through an industry-sponsored session, GeneDx will explore the gap between the availability of the medical genetics workforce and the genetic testing needs of pediatric patients.
"We are motivated to continue to push the boundaries of genomics to transform the future of healthcare," said Paul Kruszka, Chief Medical Officer at GeneDx.

Inocras to Present Enhancing Genomic Analysis in Cancer Diagnostics at the 2024 AACR Annual Meeting

Retrieved on:

星期五, 四月 5, 2024

View the full release here: https://www.businesswire.com/news/home/20240405427133/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240405427133/en/
Inocras presenting at the 2024 American Association for Cancer Research (AACR 2024) in San Diego, USA.
Our research findings presented at AACR 2024 will underscore the potential of machine learning in revolutionizing personalized cancer treatment strategies."
Inocras's participation in AACR 2024 showcases the company's relentless dedication to leveraging technological innovation to revolutionize cancer research and clinical practice.
For more information about Inocras and its groundbreaking research presented at AACR 2024, please visit Inocras.

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Retrieved on:

星期二, 三月 26, 2024

Biotechnology, Genetics, Health, Oncology, WGS, Genomics, Plasma, Congress, PPM, PSNL, NSCLC, Adenocarcinoma, Patient, Publishing, DNA, Cancer, LUAD, Lung cancer, NeXT, Neoplasm, ESMO, MRD, Medicare, Recurrence, Medical imaging

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.

Key Points:

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.
“The robust validation results in this publication provide a foundational building block towards achieving Medicare coverage for NeXT Personal,” said Richard Chen, MD, MS, Chief Medical Officer and Executive Vice President, R&D of Personalis.
“Taken together, the results show NeXT Personal’s capability for ultra-sensitive detection of ctDNA in patient plasma samples and the test’s potential to reliably inform clinicians and patients on residual cancer, cancer treatment response, and cancer recurrence through ctDNA detection, earlier than conventional detection approaches,” Chen noted.
This data from the TRACERx Study demonstrated the assay was able to find cancer nearly a year ahead of imaging and was predictive of clinical outcomes in early-stage lung cancer patients.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on:

星期一, 三月 25, 2024

Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points:

Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.
Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed.
Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument.
Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

Wipro Enters into Agreement with Desjardins to Modernize Consumer Banking Services Using its NetOxygen Platform

Retrieved on:

星期四, 三月 14, 2024

Professional Services, Technology, Finance, Consulting, Networks, Banking, WGS, Automation, Wipro, Desjardins Group, Partnership, Desjardins, Personal Services, Limited

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced that it has been selected by Desjardins to transform their credit solutions for members and clients.

Key Points:

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced that it has been selected by Desjardins to transform their credit solutions for members and clients.
This transformation program will provide Desjardins members and clients with a convenient digital lending experience that is accessible anytime, anywhere, and on any device.
It will also eliminate operational tasks through automation, enabling Desjardins employees to focus on advisory services and the handling of more complex transactions.
The NetOxygen solution is perfectly aligned with Desjardins' vision, Wipro is the natural choice of our strategic partnership in this major transformation journey."